SML3962
LTX-315 trifluoroacetate
≥95% (HPLC)
别名:
KKWWKKW(Dip)K-NH2 trifluoroacetate, LTX 315 trifluoroacetate, LTX-315 trifluoroacetate, Lys-Lys-Trp-Trp-Lys-Lys-Trp-Dip-Lys-NH2 (Dip = 3,3-diphenylalanine) trifluoroacetate, Ruxotemitide trifluoroacetate
SMILES string
[nH]1c2c(c(c1)C[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)CCCCN)Cc7c8c([nH]c7)cccc8)Cc5c6c([nH]c5)cccc6)CCCCN)CCCCN)C(=O)N[C@@H](C(c4ccccc4)c3ccccc3)C(=O)N[C@@H](CCCCN)C(=O)N)cccc2
InChI key
GGAKLYWEFZCVIT-TVEKFXMRSA-N
assay
≥95% (HPLC)
form
(Powder or Lyophilized powder or film)
storage condition
desiccated
color
white to off-white
storage temp.
-10 to -25°C
Quality Level
Biochem/physiol Actions
Mitochondrial membrane-permeabilizing cationic oncolytic peptide with cancer-selective cytotoxicity in cultures and in vivo.
LTX-315 (Ruxotemitide) is a 9-mer cationic oncolytic peptide that preferentially permeabilizes mitochondrial membranes, thereby causing partially BAX/BAK1-regulated, caspase-independent necrosis. LTX-315 exhibits cancer-selective cytotoxicity (IC50 = 1.2-7.2 μM among 47 cancer lines; normal MRC-5/HUVEC-C/RBC IC50 = 9.2/16.3/695 μM) with low inhibitory potency toward CYP450 enzymes (IC50 from 7.9 to >100 μM). Intratumoral administration results in B16 melanoma tumor necrosis and the infiltration of immune cells into the tumor parenchyma followed by complete tumor regression in mice in vivo (1 mg/50 μL i.t.). Animals cured by LTX-315 treatment are protected against B16 tumor cells re-challenge.
LTX-315 (Ruxotemitide) is a 9-mer cationic oncolytic peptide that preferentially permeabilizes mitochondrial membranes, thereby causing partially BAX/BAK1-regulated, caspase-independent necrosis. LTX-315 exhibits cancer-selective cytotoxicity (IC50 = 1.2-7.2 μM among 47 cancer lines; normal MRC-5/HUVEC-C/RBC IC50 = 9.2/16.3/695 μM) with low inhibitory potency toward CYP450 enzymes (IC50 from 7.9 to >100 μM). Intratumoral administration results in B16 melanoma tumor necrosis and the infiltration of immune cells into the tumor parenchyma followed by complete tumor regression in mice in vivo (1 mg/50 μL i.t.). Animals cured by LTX-315 treatment are protected against B16 tumor cells re-challenge.
Disclaimer
Hygroscopic
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
The oncolytic peptide LTX-315 triggers immunogenic cell death
Cell Death & Disease, 7(3) (2016)
The oncolytic peptide LTX-315 triggers necrotic cell death
Cell Cycle, 14(21), 3506-3512 (2015)
LTX-315 (Oncopore?): A short synthetic anticancer peptide and novel immunotherapeutic agent
Oncoimmunology (2014)
Discovery of a 9-mer Cationic Peptide (LTX-315) as a Potential First in Class Oncolytic Peptide
Journal of Medicinal Chemistry, 59(7), 2918-2927 (2016)
LTX-315, CAPtivating immunity with necrosis
Cell Cycle, 15(9), 1176-1177 (2016)
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持